Compare Regeneron Pharmaceuticals Inc (REGN) vs Global X SuperDividend ETF (SDIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Global X SuperDividend ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Global X SuperDividend ETF trades at $25.01. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Global X SuperDividend ETF pays none, and Global X SuperDividend ETF is trading nearer its 52-week high, Regeneron Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| REGN | SDIV | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $812.27 | $26.34 |
52-Week Low | $545.46 | $22.90 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
SDIV trades at $24.73, down 0.72% on the day, with a neutral technical signal and bearish moving averages. The ETF maintains a high yield strategy, evidenced by recent $0.18 dividends. Support is firm at $24, while resistance clusters around $25. News sentiment is mixed, highlighting its appeal for income but noting valuation concerns compared to growth-focused strategies.
Outlook hinges on income-seeking demand amid stable global small-cap value exposure. The primary opportunity is its 9%+ yield for diversification away from tech. Risks include sensitivity to interest rates and economic cycles affecting high-dividend stocks, with limited fundamental data increasing reliance on technical and sentiment factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Global X SuperDividend ETF
SDIV is an ETF that invests in 100 of the highest dividend-yielding equity securities in the world. The fund seeks to provide a high level of income to investors by selecting companies from both developed and emerging markets that have historically provided high dividend yields. By diversifying globally, SDIV aims to mitigate risks associated with focusing on a single country, while offering monthly distributions to its shareholders.
Read more on SDIV →
